Nagaharu, Keiki
Ohya, Eiko
Edahiro, Yoko
Hashimoto, Yoshinori
Ito, Tomoki
Gotoh, Akihiko
Nakamae, Mika
Kimura, Fumihiko
Koike, Michiaki
Kirito, Keita
Wada, Hideho
Usuki, Kensuke
Tanaka, Takayuki
Mori, Takehiko
Wakita, Satoshi
Saito, Toshiki I.
Saito, Akiko M.
Shimoda, Kazuya
Kurokawa, Toshiro
Tomita, Akihiro
Kiyoi, Hitoshi
Akashi, Koichi
Matsumura, Itaru
Takenaka, Katsuto
Komatsu, Norio
Ohishi, Kohshi
Tawara, Isao
Sugimoto, Yuka
Article History
Received: 9 March 2024
Accepted: 13 July 2024
First Online: 22 July 2024
Change Date: 21 August 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00277-024-05940-4
Declarations
:
: This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical approval for this study was granted by the Mie University Hospital Ethical Committee (approval number H2022-165).
: This study is retrospective in nature; therefore, the requirement for informed consent was waived by the ethics committee.
: Not applicable.
: Keiki Nagaharu reports research funds under Takeda Pharmaceutical internationals Yoko Edahiro reports research funds under contract from Meiji Seika Pharma, and an endowed chair funded by PharmaEssentia Japan K.K. Yoshinori Hashimoto reports honoraria from Takeda Pharmaceutical and Novartis Pharmaceutical, and an endowed chair funded by PharmaEssentia Japan K.K. Tomoki Ito reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Meyer Squib. Akihiko Gotoh reports honoraria from Novartis Pharma K.K., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Nihon Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Janssen Pharmaceutical K.K., Pfizer Japan Inc., Sanofi K.K., PharmaEssentia Japan K.K. Mika Nakamae reports research fund from Veritas Corporation, honoraria to her spouse from Amgen Inc., Astellas Pharma, AstraZeneca plc., Bristol-Meyer Squib, Daiichi Sankyo, Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Ltd., Nippon Shinyaku, Novartis Pharmaceutical, Ono Pharmaceutical, Otsuka Pharmaceutical, Sumitomo Pharma, and Takeda Pharmaceutical. Fumihiko Kimura reports grants from Ono Pharmaceutical and Takeda Pharmaceutical. Keita Kirito reports honoraria from Novartis Pharmaceutical, Takeda Pharmaceutical and PharmaEssentia JAPAN. Hideho Wada reports grants from Chugai Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, and Takeda Pharmaceutical. Kensuke Usuki reports research funds under contract from Abbvie Inc., Amgen Astellas BioPharma, Apellis Pharmaceutical, Astellas Pharma, Bristol-Meyer Squib, Daiichi Sankyo, Janssen Pharmaceutical, Nippon Shinyaku Pharmaceutical, Otsuka Pharmaceutical, SymBio Pharmaceutical, and Takeda Pharmaceutical, and honoraria and research funds under contract from Novartis Pharmaceutical. Takehiko Mori reports honoraria from Pfizer, Novartis Pharmaceutical, Takeda Pharmaceutical, PharmaEssentia Japan, and research funds under contract from Asahi Kasei Pharma, Chugai Pharmaceutical, Kyowa Kirin, Eisai Pharmaceutical, JCR Pharmaceuticals, Abbvie Inc., Sumitomo Pharma, CSL Behring, Japan Blood Products Organization and Otsuka Pharmaceutical. Kazuya Shimoda reports honoraria from Bristol-Meyer Squib, Celgene, Novartis Pharmaceutical, and Takeda Pharmaceutical, research funds under contract from PharmaEssentia Japan K.K., and grants from Abbvie Inc., Astellas Pharma, Chugai Pharmaceutical, Kyowa Kirin, and MSD. Akihiro Tomita reports honoraria from Takeda Pharmaceutical; research funds under contract from Kyowa Kirin, Novartis Pharmaceutical, Ono Pharmaceutical, Perseus Proteomics Inc., Pfizer, and Taiho Pharmaceutical; and honoraria and research funds under contract from Chugai Pharmaceutical. Koichi Akashi reports honoraria from Celgene and Novartis Pharmaceutical, grants from Asahi Kasei Pharma, Mochida, MSD, Mundi Pharma, Nippon Shinyaku Pharmaceutical, Ono Pharmaceutical, Shionogi, Sanofi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Toyama Chemical, Shin Nippon Biomedical Laboratories, Yakult Honsha, and Takeda Pharmaceutical, honoraria and research funds under contract from Bristol-Meyer Squib and Janssen Pharmaceutical, honoraria and grants from Abbvie Inc., Chugai Pharmaceutical, and Eisai Pharmaceutical, research funds under contract and grants from Daiichi Sankyo and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Astellas Pharma and Kyowa Kirin. Itaru Matsumura received speakers bureau fees from Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Novartis Pharma K.K., Chugai Pharmaceutical Co., Ltd., AbbVie G.K., Janssen Pharmaceutical K.K., Bristol Myers Squibb K.K. (Celgene K.K.), AstraZeneca K.K., and Otsuka Pharmaceutical Co., Ltd.; received research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd.,Asahi Kasei Pharma Corp, AbbVie G.K., Taiho Pharmaceutical Co., Ltd., and received consultancy fees from Otsuka Pharmaceutical Co., Ltd.Katsuto Takenaka reports honoraria from Novartis Pharmaceutical and MSD, grants from Astellas Pharma, Chugai Pharmaceutical, and Otsuka Pharmaceutical, honoraria, and grants from Kyowa Kirin. Norio Komatsu reports honoraria from Abbvie Inc., Celgene, and Japan Tobacco Inc., research funds under contract from FUJIFILM Wako Chemicals, Fuso-pharm, Meiji Seika Pharma, Perseus Proteomics Inc., and Pfizer, grants from Bristol-Meyer Squib, Chugai Pharmaceutical, Kyowa Kirin, and Sumitomo Dainippon Pharma, honoraria and grants from Novartis Pharmaceutical and Otsuka Pharmaceutical, honoraria, research funds under contract, and grants from Takeda Pharmaceutical, honoraria, research funds under contract, and an endowed chair funded by PharmaEssentia Japan K.K. The other authors declare no conflicts of interest. Kohishi Ohishi reports research funds under contract from PharmaEssentia Japan K.K., Abbvie Inc. Isao Tawara reports honoraria from Novartis Pharmaceutical, Sanofi, and Takeda Pharmaceutical, and honoraria and grants from Abbvie Inc. and Bristol-Meyer Squib.Yuka Sugimoto reports honoraria from PharmaEssentia Japan K.K. and Novartis Pharmaceutical and research funds under contract from Incyte Biosciences, Japan and Toyo Kohan K.K.